Overview
The Union Health Ministry has drafted amendments to the Drugs Rules, 1945. The changes aim to allow the immediate suspension of manufacturing licences for drugs that are declared NSQ on specific parameters.
Key Developments
- Licences can be suspended instantly by the Central Licensing Approving Authority or the relevant State Licensing Authority upon receipt of a government analyst’s NSQ report.
- The suspension remains until the manufacturer completes a root‑cause analysis and implements CAPA satisfactory to the licensing authority.
- Form 13, the test‑report format of the Government Analyst, will be endorsed to the DCGI, the concerned state authority, and the drug’s manufacturer/marketer.
- The draft amendments are open for public comment for 30 days after publication in the Gazette of India.
Important Facts
Under the current rules, a licence can be cancelled only after a formal show‑cause notice, creating a time lag between an NSQ declaration and regulatory action. The proposed amendment removes this lag, allowing immediate suspension based on critical quality parameters such as assay, dissolution, related substances, impurities and sterility.
The changes were discussed in the 65th meeting of the Drugs Consultative Committee on 20 December 2024 and the 92nd meeting of the Drugs Technical Advisory Board on 24 April 2025.
Exam Relevance
Understanding these amendments is crucial for GS 2 (Polity) as they illustrate how regulatory frameworks evolve to protect public health. The move strengthens post‑marketing surveillance, a key aspect of the public health governance architecture. It also highlights the role of inter‑agency coordination (DCGI, CLAA, SLA, Government Analyst) – a typical case study for questions on institutional mechanisms and accountability.
Way Forward
After the 30‑day public consultation, the Ministry will incorporate feedback and finalize the rules. Effective implementation will require:
- Capacity building for rapid testing by Government Analysts.
- Clear SOPs for manufacturers to conduct CAPA promptly.
- Robust communication channels among DCGI, CLAA, SLA and industry stakeholders.
These steps will help ensure that substandard medicines are removed from the market quickly, thereby protecting patients and reinforcing confidence in India’s pharmaceutical sector.